Crescent Biopharma (CBIO) Net Equity Issued and Repurchased (2014 - 2024)

Crescent Biopharma (CBIO) has reported Net Equity Issued and Repurchased for 8 consecutive years, with $4.0 million the latest figure, recorded in Q4 2024.

• In Q4 2024, Net Equity Issued and Repurchased changed N/A year-over-year to $4.0 million; the TTM figure through Dec 2024 stood at $4.0 million (down 86.07% YoY), while the FY2023 annual figure was $28.7 million, up 590.5% from the prior year.
• Net Equity Issued and Repurchased retreated to $4.0 million in Q4 2024 per CBIO's latest filing, from $28.7 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $28.7 million in Q1 2023 and bottomed at $1.1 million in Q4 2021.
• Historically, Net Equity Issued and Repurchased has averaged $8.6 million across 4 years, with a median of $4.3 million in 2020.
• On a YoY basis, Net Equity Issued and Repurchased climbed as much as 69.24% in 2021 and fell as far as 69.24% in 2021.
• Crescent Biopharma's Net Equity Issued and Repurchased stood at $3.7 million in 2020, then slumped by 69.24% to $1.1 million in 2021, then surged by 2419.0% to $28.7 million in 2023, then sank by 86.07% to $4.0 million in 2024.
• Business Quant data shows CBIO's Net Equity Issued and Repurchased at $4.0 million in Q4 2024, $28.7 million in Q1 2023, and $1.1 million in Q4 2021.